NeuroOne Medical Technologies Corporation

NasdaqCM:NMTC Stock Report

Market Cap: US$31.4m

NeuroOne Medical Technologies Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for NeuroOne Medical Technologies.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth16.0%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Dec 16
Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?

Jul 25
Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?

Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation

Apr 11
Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation

We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

Sep 15
We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet

Aug 03

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Jun 02
Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Companies Like NeuroOne Medical Technologies (NASDAQ:NMTC) Could Be Quite Risky

Dec 18
Companies Like NeuroOne Medical Technologies (NASDAQ:NMTC) Could Be Quite Risky

NeuroOne: Thin Film Electrodes For Diagnosis And Treatment Of Neurological Conditions

Nov 19

Will NeuroOne Medical Technologies (NASDAQ:NMTC) Spend Its Cash Wisely?

Sep 04
Will NeuroOne Medical Technologies (NASDAQ:NMTC) Spend Its Cash Wisely?

We're Not Very Worried About NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Rate

May 27
We're Not Very Worried About NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Rate

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NeuroOne Medical Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:NMTC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20233-13-14-13N/A
9/30/20233-12-13-13N/A
6/30/20235-10-9-9N/A
3/31/20234-9-9-9N/A
12/31/20224-9-9-8N/A
9/30/20222-10-8-8N/A
6/30/20220-11-11-11N/A
3/31/20220-11-10-10N/A
12/31/20210-11-10-9N/A
9/30/20210-10-9-9N/A
6/30/20212-8-6-6N/A
3/31/20212-12-5-5N/A
12/31/20202-11-4-4N/A
9/30/20202-14-4-3N/A
6/30/2020N/A-14-5-5N/A
3/31/2020N/A-9-5-5N/A
12/31/2019N/A-10-6-6N/A
9/30/2019N/A-7-6-5N/A
6/30/2019N/A-8-5-5N/A
3/31/2019N/A-7-4-4N/A
12/31/2018N/A-6-3-3N/A
9/30/2018N/A-7-3-3N/A
6/30/2018N/A-6-3-2N/A
3/31/2018N/A-6-2-2N/A
12/31/2017N/A-5-2-2N/A
9/30/2017N/A-4N/A-2N/A
3/31/2017N/A-1N/A-1N/A
12/31/2016N/A0N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NMTC's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if NMTC's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if NMTC's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NMTC's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if NMTC's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NMTC's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.